Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Sets Its Sights On Therapeutic Cancer Vaccines

This article was originally published in The Pink Sheet Daily

Executive Summary

The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.

You may also be interested in...



Vaccines Chess Game Continues With Baxter Sale To Pfizer

Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.

Global Vaccine Market At 10% Growth, Poised For Therapeutic Vaccines

Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.

Global Vaccine Market At 10% Growth, Poised For Therapeutic Vaccines

Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS076231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel